Loading...

APC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_APC_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • 53-6dot7_APC_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100711 25 µg 27€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100712 100 µg 84€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Choi JG, et al. 2020. Front Immunol. 11:598556. PubMed
  2. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  3. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  4. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  5. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  6. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  7. Li X et al. 2019. Immunity. 50(3):576-590 . PubMed
  8. O'Malley G, et al. 2018. Cancer Immunol Res. 1.240277778. PubMed
  9. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  10. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  11. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  12. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  13. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  14. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  15. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  16. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  17. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  18. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  19. Zhao X, et al. 2022. Front Mol Biosci. 9:786864. PubMed
  20. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  21. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  22. Ma Z, et al. 2016. Clin Cancer Res. 22: 2969 - 2980. PubMed
  23. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  24. Leach SM, et al. 2020. Cell Rep. 33:108337. PubMed
  25. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  26. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  27. Dong L, et al. 2021. Cancer Cell. . PubMed
  28. Castiello MC, et al. 2020. J Allergy Clin Immunol. . PubMed
  29. Wang D, et al. 2018. Immunity. 48:659. PubMed
  30. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  31. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  32. Takeda Y, et al. 2018. Innate Immun. 24:323. PubMed
  33. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  34. Riley JS, et al. 2020. Blood Adv. 4:1102. PubMed
  35. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  36. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  37. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  38. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  39. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  40. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  41. Li ZX, et al. 2022. Arch Virol. :. PubMed
  42. Ghosh S, et al. 2022. APL Bioeng. 6:036105. PubMed
  43. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  44. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  45. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  46. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  47. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  48. Blumenthal D, et al. 2020. eLife. 9:e55995.. PubMed
  49. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  50. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  51. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  52. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  53. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  54. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  55. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  56. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
  57. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  58. Wagner V, et al. 2016. Sci Transl Med. 8: 366ra164. PubMed
  59. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  60. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  61. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  62. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  63. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  64. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  65. Lee JH, et al. 2018. Transgenic Res. 27:241. PubMed
  66. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  67. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  68. Yin Y, et al. 2021. ACS Nano. 15:14347. PubMed
  69. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  70. Zhan CS, et al. 2020. FASEB J. 14006:34. PubMed
  71. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  72. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  73. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  74. Eriksson E, et al. 2016. Gene Ther. 10.1038/gt.2016.80. PubMed
  75. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  76. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  77. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  78. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  79. Li Y, et al. 2019. Oncol Rep. 41:2679. PubMed
  80. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  81. Guo H, et al. 2022. PLoS Pathog. 18:e1010857. PubMed
  82. Frey N, et al. 2022. Nat Commun. 13:1804. PubMed
  83. Zhang J, et al. 2022. Front Immunol. 13:931740. PubMed
  84. Bhattacharya P, et al. 2022. PLoS Negl Trop Dis. 16:e0010224. PubMed
  85. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  86. Yin Q, et al. 2015. PLoS One. 10: 0137808. PubMed
  87. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  88. Matsumura K, et al. 2016. J Immunol. 197: 3233 - 3244. PubMed
  89. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  90. Solanki A, et al. 2018. Development. 145. PubMed
  91. Koliaraki V et al. 2019. Cell reports. 26(3):536-545 . PubMed
  92. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  93. Riffelmacher T et al. 2017. Immunity. 47(3):466-480 . PubMed
  94. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  95. Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed
  96. Si L, et al. 2022. Nat Biotechnol. 40:1370. PubMed
  97. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  98. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  99. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  100. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  101. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  102. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  103. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  104. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  105. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  106. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  107. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  108. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  109. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  110. Divan A, et al. 2018. PLoS One. 13:e0196893. PubMed
  111. He X, et al. 2021. Small. 17:e2007165. PubMed
  112. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  113. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  114. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  115. Jeong SH, et al. 2021. Nat Commun. 12:4405. PubMed
  116. Chen Q, et al. 2016. Nat Commun. 7:13193. PubMed
  117. Hoefflin R, et al. 2020. Nat Commun. 3.313194444. PubMed
  118. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  119. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  120. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  121. Zheng Z, et al. 2020. Cell Death Dis. 0.684722222. PubMed
  122. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  123. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  124. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  125. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  126. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  127. Yi X, et al. 2020. Sci Adv. 6:eaba3546. PubMed
  128. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  129. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  130. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  131. Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed
  132. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  133. Al–Zaher AA, et al. 2018. Mol Ther Oncolytics. 0.376388889. PubMed
  134. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  135. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  136. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  137. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  138. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  139. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  140. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
  141. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  142. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  143. Ye P, et al. 2022. Front Cardiovasc Med. 8:810477. PubMed
  144. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  145. Gibbins J, et al. 2014. Blood. 124:2953. PubMed
  146. Ku C, et al. 2015. Genes Dev. 29: 1930-1941. PubMed
  147. Cook KD, et al. 2015. Immunity. 43:703-714. PubMed
  148. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  149. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  150. Wanner-Seleznik GM, et al. 2020. Immunohorizons. 0.644444444. PubMed
  151. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  152. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  153. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  154. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  155. Matsuo K, et al. 2018. J Immunol. 200:800. PubMed
  156. Takaku S, et al. 2020. Integr Cancer Ther. 19:1534735419900798. PubMed
  157. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  158. Medyouf H, et al. 2010. Blood. 115:1175. PubMed
  159. Oka Y, et al. 2020. Sci Adv. 6:. PubMed
  160. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  161. Jiang Y, et al. 2020. Adv Mater. 32:e2001808. PubMed
  162. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  163. Li H, et al. 2021. Nat Commun. 12:7149. PubMed
  164. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  165. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  166. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  167. Zhang Q, et al. 2022. Nat Commun. 13:2406. PubMed
  168. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  169. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  170. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  171. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  172. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  173. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  174. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  175. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  176. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  177. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  178. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  179. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  180. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  181. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  182. Sun S, et al. 2013. J Immunol. 190:6209. PubMed
  183. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  184. Nanou A, et al. 2021. Cell Reports. 35(8):109168. PubMed
  185. Lin YH, et al. 2018. Cancer Immunol Res. 0.25. PubMed
  186. Morelli AE, et al. 2020. Cell Rep. 30:3448. PubMed
  187. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  188. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  189. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  190. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  191. Feng Y, et al. 2022. J Nanobiotechnology. 20:193. PubMed
  192. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  193. Alexandre YO, et al. 2020. Cell Reports. 33(13):108567. PubMed
  194. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  195. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  196. Wu L, et al. 2020. Cell Rep. 33:108327. PubMed
  197. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  198. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  199. Sasaki Y, et al. 2015. PLoS One. 10: 0131176. PubMed
  200. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  201. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  202. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  203. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  204. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  205. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  206. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  207. Frazer GL, et al. 2021. J Cell Biol. 220:. PubMed
  208. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  209. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  210. Kataru RP, et al. 2022. Front Aging. 3:864860. PubMed
  211. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  212. Huber MK, et al. 2021. J Vis Exp. :. PubMed
  213. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  214. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  215. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  216. Li X, et al. 2017. Front Immunol. 8:1186. PubMed
  217. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  218. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  219. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  220. Rao L, et al. 2020. Nat Commun. 11:4909. PubMed
  221. Murata T, et al. 2020. Sci Rep. 10:13560. PubMed
  222. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  223. Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed
  224. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  225. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  226. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  227. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  228. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  229. Lu C, et al. 2020. Cancer Cell. 39(1):96-108.e6. PubMed
  230. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  231. Zhang J, et al. 2018. Oncoimmunology. 7:e1461301. PubMed
  232. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  233. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  234. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
  235. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  236. Zheng Z, et al. 2021. Biomed Res Int. 2021:5535578. PubMed
  237. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  238. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  239. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  240. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  241. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  242. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  243. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  244. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  245. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  246. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  247. Liu YW, et al. 2022. JCI Insight. 7:. PubMed
  248. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  249. Chen B, et al. 2021. Cell. 184:6262. PubMed
  250. Smith LK, et al. 2021. Elife. 10:. PubMed
  251. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
  252. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  253. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  254. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  255. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  256. Cong L, et al. 2021. Breast Cancer Res. 23:51. PubMed
  257. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  258. Zhou P, et al. 2022. Mol Ther Oncolytics. 25:236. PubMed
  259. Zheng Y, et al. 2022. Transl Res. :. PubMed
  260. Funk KE, et al. 2021. Aging Cell. 20:e13412. PubMed
  261. Galeano Nio JL, et al. 2020. eLife. 9:00. PubMed
  262. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  263. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
  264. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  265. Bessell CA, et al. 2020. JCI Insight. 5:. PubMed
  266. Li C, et al. 2022. Front Cell Dev Biol. 10:913824. PubMed
  267. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  268. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
RRID
AB_312750 (BioLegend Cat. No. 100711)
AB_312751 (BioLegend Cat. No. 100712)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account